Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Breast cancer-induced bone destruction prevented by apoptosis-inducing ligand
July 14th, 2006
According to recent research from Australia published in the journal Cancer Research, Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) prevents breast cancer-induced bone destruction in a mouse. "Breast cancer is the most common carcinoma that metastasizes to bone. To examine the efficacy of recombinant soluble Apo2 ligand (Apo2L)/TRAIL against breast cancer growth in bone, we established a mouse model in which MDA-MB-231 human breast cancer cells were transplanted directly into the marrow cavity of the tibiae of athymic nude mice producing osteolytic lesions in the area of injection," wrote L. Thai and colleagues, Royal Adelaide...
Source: Genomics & Genetics Weekly (2006-07-14)
|
